Gilead Sciences, Inc. GILD34.SA Stock
Gilead Sciences, Inc. Price Chart
Gilead Sciences, Inc. GILD34.SA Financial and Trading Overview
| Gilead Sciences, Inc. stock price | 173.84 BRL |
| Previous Close | 199.37 BRL |
| Open | 0 BRL |
| Bid | 188.86 BRL x 0 |
| Ask | 192.28 BRL x 0 |
| Day's Range | 0 - 0 BRL |
| 52 Week Range | 0 - 235.55 BRL |
| Volume | 0 BRL |
| Avg. Volume | 22 BRL |
| Market Cap | 472.3B BRL |
| Beta (5Y Monthly) | 0.40669 |
| PE Ratio (TTM) | 17.611164 |
| EPS (TTM) | 11.46 BRL |
| Forward Dividend & Yield | 7.72 (3.85%) |
| Ex-Dividend Date | June 14, 2023 |
| 1y Target Est | N/A |
GILD34.SA Valuation Measures
| Enterprise Value | 268.93B BRL |
| Trailing P/E | 17.611164 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.464724 |
| Price/Book (mrq) | 11.252303 |
| Enterprise Value/Revenue | 9.945 |
| Enterprise Value/EBITDA | 21.585 |
Trading Information
Gilead Sciences, Inc. Stock Price History
| Beta (5Y Monthly) | 0.40669 |
| 52-Week Change | 33.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 235.55 BRL |
| 52 Week Low | 0 BRL |
| 50-Day Moving Average | 200.11 BRL |
| 200-Day Moving Average | 203.68 BRL |
GILD34.SA Share Statistics
| Avg. Volume (3 month) | 22 BRL |
| Avg. Daily Volume (10-Days) | 12 BRL |
| Shares Outstanding | 2.49B |
| Float | 1.25B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.0010% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.94 |
| Trailing Annual Dividend Yield | 1.47% |
| 5 Year Average Dividend Yield | 378.00% |
| Payout Ratio | 0.6693 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 20.64% |
| Operating Margin (ttm) | 37.86% |
| Gross Margin | 79.16% |
| EBITDA Margin | 46.07% |
Management Effectiveness
| Return on Assets (ttm) | 10.24% |
| Return on Equity (ttm) | 27.11% |
Income Statement
| Revenue (ttm) | 27.04B BRL |
| Revenue Per Share (ttm) | 21.58 BRL |
| Quarterly Revenue Growth (yoy) | -3.59% |
| Gross Profit (ttm) | 21.62B BRL |
| EBITDA | 12.46B BRL |
| Net Income Avi to Common (ttm) | 5.58B BRL |
| Diluted EPS (ttm) | 10.75 |
| Quarterly Earnings Growth (yoy) | 5215.80% |
Balance Sheet
| Total Cash (mrq) | 6.52B BRL |
| Total Cash Per Share (mrq) | 5.23 BRL |
| Total Debt (mrq) | 25.24B BRL |
| Total Debt/Equity (mrq) | 120.54 BRL |
| Current Ratio (mrq) | 1.278 |
| Book Value Per Share (mrq) | 16.825 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 8.98B BRL |
| Levered Free Cash Flow (ttm) | 8.51B BRL |
Profile of Gilead Sciences, Inc.
| Country | Brazil |
| State | CA |
| City | Foster City |
| Address | 333 Lakeside Drive |
| ZIP | 94404 |
| Phone | 650 574 3000 |
| Website | https://www.gilead.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | 17000 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Q&A For Gilead Sciences, Inc. Stock
What is a current GILD34.SA stock price?
Gilead Sciences, Inc. GILD34.SA stock price today per share is 173.84 BRL.
How to purchase Gilead Sciences, Inc. stock?
You can buy GILD34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gilead Sciences, Inc.?
The stock symbol or ticker of Gilead Sciences, Inc. is GILD34.SA.
Which industry does the Gilead Sciences, Inc. company belong to?
The Gilead Sciences, Inc. industry is Drug Manufacturers-General.
How many shares does Gilead Sciences, Inc. have in circulation?
The max supply of Gilead Sciences, Inc. shares is 2.49B.
What is Gilead Sciences, Inc. Price to Earnings Ratio (PE Ratio)?
Gilead Sciences, Inc. PE Ratio is 15.16928400 now.
What was Gilead Sciences, Inc. earnings per share over the trailing 12 months (TTM)?
Gilead Sciences, Inc. EPS is 11.46 BRL over the trailing 12 months.
Which sector does the Gilead Sciences, Inc. company belong to?
The Gilead Sciences, Inc. sector is Healthcare.